When potassium is markedly elevated and the heart is at risk, the first priority is to protect cardiac membranes. IV calcium gluconate rapidly stabilizes the myocardial cell membranes, reducing excitability and preventing life-threatening arrhythmias, even before any change in serum potassium occurs. After the heart is stabilized, the next step is to lower the extracellular potassium by shifting it into cells—administer insulin with glucose, and/or a beta-agonist such as albuterol. These moves can rapidly decrease potassium levels within minutes to an hour. Continuous ECG monitoring is essential during this process to track response and catch any evolving changes. Bicarbonate can be helpful if metabolic acidosis is present, but it does not provide the immediate membrane stabilization that calcium does. Oral potassium binders act more slowly and are not used for immediate stabilization. Fluid restriction and observation do not address the urgent risk of arrhythmia in this scenario. In a CKD patient with significant hyperkalemia, dialysis is considered if potassium remains high or if there are ongoing risks or refractory cases, as it provides definitive potassium removal.

Assessing AV graft patency through palpation findings. A properly functioning AV graft should have a palpable thrill along the graft, which is a vibrating sensation felt over the access site as blood moves rapidly through the artificial conduit. This thrill indicates that there is ongoing flow through the graft, meaning the graft is not narrowed or occluded. Documenting that the thrill is present and can be palpated provides a clear, objective sign of patency. While a bruit heard over the graft can also suggest flow, it is less definitive for documentation because sounds can be variable due to technique, frequency, or ambient factors, and a bruit alone may not always reliably confirm patency. Absence of a thrill raises concern for stenosis or thrombosis and would prompt further evaluation. Redness and warmth around the graft point more toward irritation or infection rather than functioning flow. Therefore, noting that a thrill is present and palpated best reflects a functioning AV graft.

Immunosuppressive therapy must protect the transplanted organ while avoiding excessive suppression of the immune system. The practical way to achieve this balance is by regularly checking drug trough levels and adjusting dosing to keep exposure within a target range. Too little immunosuppression raises the risk of rejection, while too much increases infection risk and other toxicities. Individual factors like absorption, metabolism, drug interactions, kidney function, and adherence vary a lot, so fixed doses won’t fit every patient—ongoing monitoring plus clinical assessment guide titration. In someone with CKD, drug handling can be altered and some agents can be nephrotoxic, making careful monitoring even more important. The goal isn’t to eliminate infections or guarantee no rejection; it’s to minimize both risks by maintaining appropriate immunosuppressive levels through regular monitoring.

Peritoneal dialysis introduces dialysate into the peritoneal cavity, creating a potential route for infection. The most common early complication is infection of the peritoneal cavity—peritonitis—often from contamination during exchanges or from the catheter exit site. It typically presents with abdominal pain and cloudy dialysate effluent, sometimes accompanied by fever. Prompt evaluation and treatment with broad-spectrum intraperitoneal antibiotics that cover both Gram-positive and Gram-negative organisms are essential, and catheter removal may be needed if the infection is persistent or fungal. While hypertension, electrolyte shifts like hypokalemia, and issues such as air leaks can occur with PD, they are not as characteristic or common in the SAMPLEearly period as peritonitis.